ES2559446T3 - Desmopresina para reducir micciones nocturnas - Google Patents
Desmopresina para reducir micciones nocturnas Download PDFInfo
- Publication number
- ES2559446T3 ES2559446T3 ES11728387.9T ES11728387T ES2559446T3 ES 2559446 T3 ES2559446 T3 ES 2559446T3 ES 11728387 T ES11728387 T ES 11728387T ES 2559446 T3 ES2559446 T3 ES 2559446T3
- Authority
- ES
- Spain
- Prior art keywords
- desmopressin
- urination
- nocturnal
- dose
- baseline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000027939 micturition Effects 0.000 title claims abstract description 107
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 title claims abstract description 82
- 229960004281 desmopressin Drugs 0.000 title claims abstract description 74
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 title claims abstract description 74
- 230000000422 nocturnal effect Effects 0.000 claims abstract description 106
- 230000009467 reduction Effects 0.000 claims abstract description 50
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 239000012458 free base Substances 0.000 claims abstract description 11
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical class C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 claims description 11
- 229960002845 desmopressin acetate Drugs 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 229940068196 placebo Drugs 0.000 description 77
- 239000000902 placebo Substances 0.000 description 77
- 238000011282 treatment Methods 0.000 description 68
- 210000002700 urine Anatomy 0.000 description 66
- 206010029446 nocturia Diseases 0.000 description 56
- 230000008859 change Effects 0.000 description 43
- 230000007423 decrease Effects 0.000 description 37
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 20
- 229910052708 sodium Inorganic materials 0.000 description 20
- 239000011734 sodium Substances 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 17
- 238000012544 monitoring process Methods 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 12
- 206010021036 Hyponatraemia Diseases 0.000 description 10
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 230000004622 sleep time Effects 0.000 description 10
- 230000002485 urinary effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 208000004880 Polyuria Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000002686 anti-diuretic effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000003860 sleep quality Effects 0.000 description 5
- 206010021639 Incontinence Diseases 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000002618 waking effect Effects 0.000 description 4
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 230000001272 neurogenic effect Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 208000008967 Enuresis Diseases 0.000 description 2
- 206010016275 Fear Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 208000010340 Sleep Deprivation Diseases 0.000 description 2
- 206010046555 Urinary retention Diseases 0.000 description 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 2
- 108010004977 Vasopressins Proteins 0.000 description 2
- 102000002852 Vasopressins Human genes 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000002060 circadian Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 208000005346 nocturnal enuresis Diseases 0.000 description 2
- 208000001797 obstructive sleep apnea Diseases 0.000 description 2
- 230000000505 pernicious effect Effects 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000022925 sleep disturbance Diseases 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 229960003726 vasopressin Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 101800001144 Arg-vasopressin Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 229930028154 D-arginine Natural products 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000023783 Genitourinary tract disease Diseases 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010053198 Inappropriate antidiuretic hormone secretion Diseases 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- 206010059240 Lymphostasis Diseases 0.000 description 1
- 206010027566 Micturition urgency Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 206010034268 Pelvic prolapse Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229940124538 antidiuretic agent Drugs 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Chemical group 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 210000004937 luminal membrane Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 206010034260 pelvic mass Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960005461 torasemide Drugs 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/732,161 US20100286045A1 (en) | 2008-05-21 | 2010-03-25 | Methods comprising desmopressin |
| US732161 | 2010-03-25 | ||
| PCT/IB2011/001010 WO2012001469A1 (en) | 2010-03-25 | 2011-03-22 | Desmopressin for reducing nocturnal voids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2559446T3 true ES2559446T3 (es) | 2016-02-12 |
Family
ID=44365354
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11728387.9T Active ES2559446T3 (es) | 2010-03-25 | 2011-03-22 | Desmopresina para reducir micciones nocturnas |
| ES15184741T Active ES2708973T3 (es) | 2010-03-25 | 2011-03-22 | Desmopresina para reducir micciones nocturnas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15184741T Active ES2708973T3 (es) | 2010-03-25 | 2011-03-22 | Desmopresina para reducir micciones nocturnas |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20100286045A1 (enExample) |
| EP (3) | EP3449908A1 (enExample) |
| JP (3) | JP6253977B2 (enExample) |
| CN (4) | CN102821776A (enExample) |
| CA (1) | CA2793502A1 (enExample) |
| DK (2) | DK3006036T3 (enExample) |
| ES (2) | ES2559446T3 (enExample) |
| HR (1) | HRP20190104T1 (enExample) |
| HU (1) | HUE027417T2 (enExample) |
| LT (1) | LT3006036T (enExample) |
| PL (2) | PL3006036T3 (enExample) |
| PT (2) | PT3006036T (enExample) |
| RS (1) | RS58224B1 (enExample) |
| SI (1) | SI3006036T1 (enExample) |
| TR (1) | TR201900240T4 (enExample) |
| WO (1) | WO2012001469A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100286045A1 (en) | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
| US11963995B2 (en) | 2008-05-21 | 2024-04-23 | Ferring B.V. | Methods comprising desmopressin |
| US20160098530A1 (en) * | 2014-10-07 | 2016-04-07 | David A. DILL | Devices and methods for managing risk profiles |
| EP3868370A4 (en) * | 2018-10-17 | 2022-06-29 | Nippon Chemiphar Co., Ltd. | Therapeutic or prophylactic agent for nocturia |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| US20240009133A1 (en) | 2020-11-16 | 2024-01-11 | Orcosa Inc. | Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs |
| WO2024211393A2 (en) | 2023-04-04 | 2024-10-10 | Tulex Pharmaceuticals Inc. | Desmopressin oral compositions |
Family Cites Families (154)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH495957A (de) | 1966-09-15 | 1970-09-15 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids |
| US4316893A (en) | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| US4285858A (en) | 1979-10-30 | 1981-08-25 | Mt. Sinai School Of Medicine Of The City University Of N.Y. | Vasopressin analogs |
| US4263283A (en) | 1980-05-16 | 1981-04-21 | Ferring Pharmaceuticals, Inc. | Method for prophylaxis and/or treatment of sickle cell disease |
| GB2111423B (en) | 1981-12-02 | 1985-06-26 | Wyeth John & Brother Ltd | Making quick-dissolving pills |
| EP0084705B1 (en) | 1981-12-11 | 1987-01-14 | JOHN WYETH & BROTHER LIMITED | Process for preparing solid shaped articles |
| US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
| SE8306367L (sv) | 1983-11-18 | 1985-05-19 | Ferring Ab | Antidiuretiskt verkande farmaceutiskt preparat |
| US4863737A (en) | 1985-05-01 | 1989-09-05 | University Of Utah | Compositions and methods of manufacture of compressed powder medicaments |
| US4588580B2 (en) | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
| IE60941B1 (en) | 1986-07-10 | 1994-09-07 | Elan Transdermal Ltd | Transdermal drug delivery device |
| US4878892A (en) | 1987-02-10 | 1989-11-07 | Drug Delivery Systems Inc. | Electrolytic transdermal delivery of polypeptides |
| US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
| DK365389D0 (da) | 1989-07-24 | 1989-07-24 | Fertin Lab As | Antifungalt tyggegummipraeparat |
| US5091186A (en) | 1989-08-15 | 1992-02-25 | Cygnus Therapeutic Systems | Biphasic transdermal drug delivery device |
| TW279133B (enExample) | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| SE9101022D0 (sv) | 1991-01-09 | 1991-04-08 | Paal Svedman | Medicinsk suganordning |
| US6746678B1 (en) | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
| AU653026B2 (en) | 1991-06-07 | 1994-09-15 | Teikoku Seiyaku Kabushiki Kaisha | Physiologically active polypeptide-containing pharmaceutical composition |
| KR100256715B1 (ko) | 1991-08-26 | 2000-05-15 | 스티븐 에프. 웨인스톡 | 치료제의 설하 또는 구강 투여를 위한 조성물 |
| FI943042A0 (fi) | 1991-12-24 | 1994-06-23 | Yamanouchi Pharma Co Ltd | Suuontelossa hajoava valmiste ja sen valmistus |
| US5298256A (en) | 1992-04-28 | 1994-03-29 | Corint, Ltd. | Desmopressin buccal patch composition |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5343672A (en) | 1992-12-01 | 1994-09-06 | Scherer Ltd R P | Method for manufacturing freeze dried dosages in a multilaminate blister pack |
| CA2090738C (en) | 1993-02-24 | 1996-05-21 | Hema-Quebec | Use of paf |
| SE9300937L (sv) | 1993-03-19 | 1994-09-20 | Anne Fjellestad Paulsen | Komposition för oral administrering av peptider |
| SE501677C2 (sv) | 1993-06-18 | 1995-04-10 | Ferring Bv | Biologiskt aktiva vasopressinanaloger, farmaceutiska preparat innehållande dem samt deras användning för framställning av läkemedel |
| US5482931A (en) | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
| ES2149880T3 (es) | 1993-06-29 | 2000-11-16 | Ferring Bv | Sintesis de peptidos ciclicos. |
| ES2158898T3 (es) | 1993-06-29 | 2001-09-16 | Ferring Bv | Composiciones para la administracion de desmopresina por via nasal. |
| US5674850A (en) | 1993-12-23 | 1997-10-07 | Ferring Ab | High purity desmopressin produced in large single batches |
| US5500413A (en) | 1993-06-29 | 1996-03-19 | Ferring Ab | Process for manufacture of 1-deamino-8-D-arginine vasopressin |
| US5985835A (en) | 1993-12-23 | 1999-11-16 | Ferring B.V. | Desmopressin for nocturia, incontinence and enuresis |
| WO1995014037A1 (en) | 1993-11-17 | 1995-05-26 | Ibah, Inc. | Transparent liquid for encapsulated drug delivery |
| SE9400918L (sv) | 1994-03-18 | 1995-09-19 | Anne Fjellstad Paulsen | Stabiliserad komposition för oral administrering av peptider |
| JP2551742B2 (ja) | 1994-05-23 | 1996-11-06 | 三星電機株式会社 | 医薬品投与用皮膚傷形成装置 |
| SE518619C2 (sv) | 1994-12-09 | 2002-10-29 | Gs Dev Ab | Komposition för reglerad frisättning innehållande monokaproin |
| GB9502879D0 (en) | 1995-02-14 | 1995-04-05 | Oxford Biosciences Ltd | Particle delivery |
| IL113459A (en) | 1995-04-23 | 2000-07-16 | Electromagnetic Bracing System | Electrophoretic cuff apparatus |
| US5843016A (en) | 1996-03-18 | 1998-12-01 | Physion S.R.L. | Electromotive drug administration for treatment of acute urinary outflow obstruction |
| TW411277B (en) | 1996-05-13 | 2000-11-11 | Hisamitsu Pharmaceutical Co | Percutaneous tape preparation containing fentanyl |
| GB9612629D0 (en) | 1996-06-17 | 1996-08-21 | Oxford Biosciences Ltd | Method for providing dense particle compositions for use in transdermal particle delivery |
| DE69719761T2 (de) | 1996-06-18 | 2003-12-18 | Alza Corp., Palo Alto | Vorrichtung zur verbesserung der transdermalen verabreichung von medikamenten oder der abnahme von körperflüssigkeiten |
| US5763398A (en) | 1996-06-20 | 1998-06-09 | Ferring B.V. | Nasal administration of desmopressin |
| US5922680A (en) | 1996-10-23 | 1999-07-13 | Ferring, B.V. | Stabilized composition for oral administration of peptides |
| SE9604341D0 (sv) | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
| FR2758195B1 (fr) | 1997-01-09 | 1999-02-26 | Sgs Thomson Microelectronics | Coprocesseur d'arithmetique modulaire comprenant deux circuits de multiplication operant en parallele |
| US5821230A (en) | 1997-04-11 | 1998-10-13 | Ferring Bv | GnRH antagonist decapeptides |
| US6194407B1 (en) | 1997-07-30 | 2001-02-27 | American Home Products Corporation | Tricyclic pyrido vasopressin agonists |
| US6511974B1 (en) | 1997-07-30 | 2003-01-28 | Wyeth | Tricyclic vasopressin agonists |
| US5932745A (en) | 1997-07-30 | 1999-08-03 | American Home Products Corporation | Process for converting propargylic amine-N-oxides to enaminones |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| US7153845B2 (en) | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| US20040018241A1 (en) | 1997-09-26 | 2004-01-29 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
| US6322532B1 (en) | 1998-06-24 | 2001-11-27 | 3M Innovative Properties Company | Sonophoresis method and apparatus |
| US7138393B2 (en) | 1998-07-24 | 2006-11-21 | Wyeth | Biologically active vasopressin agonist metabolites |
| US6090803A (en) | 1998-07-24 | 2000-07-18 | American Home Products Corporation | Tricyclic vasopressin agonists |
| US6148232A (en) | 1998-11-09 | 2000-11-14 | Elecsys Ltd. | Transdermal drug delivery and analyte extraction |
| GB9827292D0 (en) | 1998-12-12 | 1999-02-03 | Univ Strathclyde | Freeze drying |
| US6406455B1 (en) | 1998-12-18 | 2002-06-18 | Biovalve Technologies, Inc. | Injection devices |
| US20060025387A1 (en) | 1998-12-23 | 2006-02-02 | Cytoscan Sciences Llc | Compositions and methods for the treatment of disorders of the central and peripheral nervous systems |
| GB9901819D0 (en) | 1999-01-27 | 1999-03-17 | Scherer Corp R P | Pharmaceutical compositions |
| US6235900B1 (en) | 1999-02-04 | 2001-05-22 | American Home Products Corporation | Tricyclic pyridine N-oxides vasopressin agonists |
| US6344451B1 (en) | 1999-02-04 | 2002-02-05 | American Home Products | Pyrrolobenzodiazepine carboxyamide vasopressin agonists |
| US6620807B1 (en) | 1999-02-04 | 2003-09-16 | Wyeth | Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists |
| US6297234B1 (en) | 1999-02-04 | 2001-10-02 | American Home Products Corporation | Arylthiophene vasopressin agonists |
| TWI271198B (en) | 1999-02-15 | 2007-01-21 | Dainippon Sumitomo Pharma Co | Tables disintegrating rapidly in the oral cavity |
| US6314317B1 (en) | 1999-02-18 | 2001-11-06 | Biovalve Technologies, Inc. | Electroactive pore |
| AR014640A1 (es) | 1999-02-23 | 2001-03-28 | Univ Nac Quilmes | UNA COMPOSICíoN FARMACÉUTICA INHIBIDORA DE LA DISEMINACIoN METASTÁSICA DURANTE LA CIRUGíA DE UN TUMOR CANCEROSO, UN PROCEDIMENTO DE PREPARACIoN Y UN KIT PARA UNA FORMULACIoN INYECTABLE. |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6210699B1 (en) | 1999-04-01 | 2001-04-03 | Watson Pharmaceuticals, Inc. | Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| WO2001022322A2 (en) | 1999-09-20 | 2001-03-29 | Ethentica, Inc. | Electronic commerce with cryptographic authentication |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| GB2355454A (en) | 1999-10-20 | 2001-04-25 | Ferring Bv | Antidiuretic agents |
| US6558695B2 (en) | 1999-12-16 | 2003-05-06 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers |
| GB0000079D0 (en) | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
| ATE501751T1 (de) | 2000-01-07 | 2011-04-15 | Valeritas Inc | Injektionsvorrichtung |
| US20070032410A1 (en) | 2000-01-11 | 2007-02-08 | Atossa Healthcare, Inc. | Compositions and methods for the treatment of psychiatric disorders |
| AT409081B (de) | 2000-02-16 | 2002-05-27 | Gebro Pharma Gmbh | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung |
| GB0015601D0 (en) | 2000-06-26 | 2000-08-16 | Ferring Bv | Novel antidiuretic agents |
| TWI287984B (en) | 2000-10-17 | 2007-10-11 | Wyeth Corp | Pharmaceutical composition for modulating bladder function |
| WO2002094368A1 (en) | 2000-10-26 | 2002-11-28 | Alza Corporation | Transdermal drug delivery devices having coated microprotrusions |
| ES2717656T3 (es) | 2000-11-30 | 2019-06-24 | Valeritas Inc | Dispositivo con microsonda amovible sustancialmente libre sobre el alojamiento |
| WO2002051470A2 (en) | 2000-11-30 | 2002-07-04 | Biovalve Technologies, Inc. | Injection systems |
| WO2002064193A2 (en) | 2000-12-14 | 2002-08-22 | Georgia Tech Research Corporation | Microneedle devices and production thereof |
| US7027478B2 (en) | 2000-12-21 | 2006-04-11 | Biovalve Technologies, Inc. | Microneedle array systems |
| JP5354763B2 (ja) | 2001-03-16 | 2013-11-27 | アルザ・コーポレーシヨン | フェンタニルを投与するための経皮的張り付け剤 |
| EP1381370B1 (en) | 2001-04-12 | 2007-03-07 | Wyeth | N-biphenylcarbonyl- and n-phenylpyridylcarbonyl substituted bi- and tricyclic azepines and diazepines as vasopressing agonists |
| DK1381608T3 (da) | 2001-04-12 | 2008-02-04 | Wyeth Corp | Cyclohexylphenylvasopressinagonister |
| US7022699B2 (en) | 2001-04-12 | 2006-04-04 | Wyeth | Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators |
| US7615234B2 (en) | 2001-09-11 | 2009-11-10 | Glide Pharmaceutical Technologies Limited | Drug delivery technology |
| BR0212494A (pt) | 2001-09-13 | 2004-08-24 | Kissei Pharmaceutical | Cristais de derivados de hidróxinorefedrina |
| US6723077B2 (en) | 2001-09-28 | 2004-04-20 | Hewlett-Packard Development Company, L.P. | Cutaneous administration system |
| US6893655B2 (en) | 2001-10-09 | 2005-05-17 | 3M Innovative Properties Co. | Transdermal delivery devices |
| MY148466A (en) | 2001-10-26 | 2013-04-30 | Merck Frosst Canada Ltd | Granule formulation |
| ES2327620T3 (es) | 2001-11-16 | 2009-11-02 | Astellas Pharma Inc. | Derivado de 4,4-difluoro-1,2,3,4-tetraidro-5h-1-benzacepina o sales del mismo. |
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| NZ535861A (en) | 2002-05-07 | 2006-11-30 | Ferring Bv | Desmopressin acetate in an orodispersible dosage form that disintegrates in the mouth within 10 seconds |
| AU2003269747A1 (en) * | 2002-05-15 | 2003-12-02 | Sun Pharmaceutical Industries Limited | A stable aqueous composition of a peptide |
| US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
| GB2421689B (en) | 2002-08-05 | 2007-03-07 | Caretek Medical Ltd | Drug delivery system |
| EP1590033A2 (en) | 2002-09-30 | 2005-11-02 | Alza Corporation | Drug delivery device having coated microprojections incorporating vasoconstrictors |
| CA2501389C (en) | 2002-10-09 | 2013-01-08 | Toray Industries, Inc. | Remedies or preventives for frequent urination or urinary incontinence and morphinan derivatives having nitrogen-containing heterocyclic group |
| US7383084B2 (en) | 2002-10-31 | 2008-06-03 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
| EP1428526A1 (en) | 2002-12-13 | 2004-06-16 | Rijksuniversiteit Groningen | Formulation for fast dissolution of lipophilic compounds |
| DE10259934B3 (de) | 2002-12-20 | 2004-10-14 | H.C. Starck Gmbh | Verfahren zur Herstellung von Formteilen aus Niob oder Tantal durch elektrochemisches Ätzen und so erhältliche Formteile |
| AR042815A1 (es) | 2002-12-26 | 2005-07-06 | Alza Corp | Dispositivo de suministro de agente activo que tiene miembros compuestos |
| NZ542815A (en) | 2003-04-28 | 2009-01-31 | Astellas Pharma Inc | 4,4-Difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or salt thereof |
| US20060193825A1 (en) | 2003-04-29 | 2006-08-31 | Praecis Phamaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| US7094545B2 (en) | 2003-04-30 | 2006-08-22 | Ferring Bv | Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
| EP1638468B1 (en) | 2003-06-30 | 2007-08-15 | Alza Corporation | Method for coating skin piercing microprojections |
| ATE301990T1 (de) | 2003-07-25 | 2005-09-15 | Ferring Bv | Pharmazeutische desmopressin-zubereitung als feste darreichungsform und methode zu ihrer herstellung |
| CN1826099B (zh) | 2003-07-25 | 2010-06-09 | 凡林有限公司 | 固体剂型药物组合物及其制造方法 |
| US6930932B2 (en) | 2003-08-27 | 2005-08-16 | Hewlett-Packard Development Company, L.P. | Data signal reception latch control using clock aligned relative to strobe signal |
| WO2005042054A2 (en) | 2003-10-24 | 2005-05-12 | Alza Corporation | Pretreatment method and system for enhancing transdermal drug delivery |
| EP1680057A4 (en) | 2003-10-24 | 2007-10-31 | Alza Corp | DEVICE AND METHOD FOR IMPROVING TRANSDERMAL DRUG DELIVERY |
| WO2005044333A2 (en) | 2003-10-31 | 2005-05-19 | Alza Corporation | Self-actuating applicator for microprojection array |
| CA2866501A1 (en) * | 2003-11-10 | 2005-05-26 | Allergan, Inc. | Pharmaceutical compositions including low dosages of desmopressin |
| ES2260563T3 (es) | 2003-11-13 | 2006-11-01 | Ferring B.V. | Paquete de blister y forma farmaceutica solida para ello. |
| FR2862230B1 (fr) | 2003-11-17 | 2005-12-16 | Rossignol Sa | Fixation de surf |
| US7018653B2 (en) | 2003-12-29 | 2006-03-28 | Ferring B.V. | Method for preparing solid dosage form of desmopressin |
| ES2254858T3 (es) | 2003-12-29 | 2006-06-16 | Ferring B.V. | Metodo para preparar una forma farmaceutica solida de desmopresina. |
| CN1946452A (zh) | 2004-01-09 | 2007-04-11 | 阿尔扎公司 | 频率促进的药物透皮释放方法和系统 |
| GB0406048D0 (en) * | 2004-03-18 | 2004-04-21 | Ardana Bioscience Ltd | Drug formulations |
| HRP20160455T1 (hr) | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| US7097776B2 (en) | 2004-10-22 | 2006-08-29 | Hewlett-Packard Development Company, L.P. | Method of fabricating microneedles |
| US20060093658A1 (en) | 2004-10-26 | 2006-05-04 | Gayatri Sathyan | Apparatus and method for transdermal delivery of desmopressin |
| CN100339081C (zh) | 2004-11-10 | 2007-09-26 | 范敏华 | 一种氯雷他定口腔崩解片剂的制备方法 |
| US20080009801A1 (en) | 2004-12-02 | 2008-01-10 | Nickel Janice H | Method for dispensing material into a drug delivery device |
| US7180274B2 (en) | 2004-12-10 | 2007-02-20 | Aimtron Technology Corp. | Switching voltage regulator operating without a discontinuous mode |
| MX2007012883A (es) | 2005-04-22 | 2007-12-10 | Wyeth Corp | Derivados de dihidrobenzofurano y usos de los mismos. |
| GT200600159A (es) | 2005-04-22 | 2007-03-14 | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| AR056320A1 (es) | 2005-04-22 | 2007-10-03 | Wyeth Corp | Derivados de cromano y cromeno, procesos de obtencion, composiciones farmaceuticas y usos de los mismos |
| US7368477B2 (en) | 2005-04-22 | 2008-05-06 | Wyeth | Benzofuranyl alkanamine derivatives and uses thereof |
| MX2007012936A (es) | 2005-04-22 | 2008-01-11 | Wyeth Corp | Derivados de dihidrobenzofurano y usos de los mismos. |
| US7856263B2 (en) | 2005-04-22 | 2010-12-21 | Travanti Pharma Inc. | Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis |
| TW200716106A (en) | 2005-04-24 | 2007-05-01 | Wyeth Corp | Methods for modulating bladder function |
| WO2006138719A2 (en) | 2005-06-17 | 2006-12-28 | Georgia Tech Research Corporation | Coated microstructures and method of manufacture thereof |
| EP1904158B1 (en) | 2005-06-24 | 2013-07-24 | 3M Innovative Properties Company | Collapsible patch with microneedle array |
| WO2007021970A2 (en) | 2005-08-15 | 2007-02-22 | Praecis Pharmaceuticals, Inc. | Stable pharmaceutical formulations and methods of use thereof |
| WO2007083323A2 (en) | 2006-01-23 | 2007-07-26 | Panacea Biotec Limited. | Modified release oral dosage form comprising desmopressin |
| CA2584456C (en) | 2006-03-02 | 2008-07-22 | Ferring International Center S.A. | Composition comprising desmopressin |
| WO2007127976A2 (en) | 2006-05-01 | 2007-11-08 | Georgia Tech Research Corporation | Particle based molding |
| CA2988753A1 (en) | 2007-08-06 | 2009-02-12 | Serenity Pharmaceuticals, Llc | Methods and devices for desmopressin drug delivery |
| LT3085381T (lt) | 2008-05-21 | 2018-06-11 | Ferring B.V. | Burnoje disperguojamas desmopresinas, skirtas naktinio šlapinimosi netrikdomo miego periodo pailginimui |
| US20100286045A1 (en) | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
| JP5151774B2 (ja) | 2008-07-29 | 2013-02-27 | 株式会社リコー | クリーニング装置、プロセスユニット及び画像形成装置 |
| US20150306170A1 (en) | 2012-11-21 | 2015-10-29 | Ferring B.V. | Composition for immediate and extended release |
-
2010
- 2010-03-25 US US12/732,161 patent/US20100286045A1/en not_active Abandoned
-
2011
- 2011-03-22 SI SI201131648T patent/SI3006036T1/sl unknown
- 2011-03-22 EP EP18196338.0A patent/EP3449908A1/en not_active Withdrawn
- 2011-03-22 PL PL15184741T patent/PL3006036T3/pl unknown
- 2011-03-22 PT PT15184741T patent/PT3006036T/pt unknown
- 2011-03-22 EP EP11728387.9A patent/EP2550007B1/en active Active
- 2011-03-22 DK DK15184741.5T patent/DK3006036T3/en active
- 2011-03-22 PT PT117283879T patent/PT2550007E/pt unknown
- 2011-03-22 CA CA2793502A patent/CA2793502A1/en not_active Withdrawn
- 2011-03-22 CN CN2011800154945A patent/CN102821776A/zh active Pending
- 2011-03-22 TR TR2019/00240T patent/TR201900240T4/tr unknown
- 2011-03-22 JP JP2013500608A patent/JP6253977B2/ja active Active
- 2011-03-22 CN CN201710490960.4A patent/CN107252474A/zh active Pending
- 2011-03-22 CN CN201911211683.4A patent/CN110898207A/zh active Pending
- 2011-03-22 EP EP15184741.5A patent/EP3006036B1/en active Active
- 2011-03-22 ES ES11728387.9T patent/ES2559446T3/es active Active
- 2011-03-22 ES ES15184741T patent/ES2708973T3/es active Active
- 2011-03-22 LT LTEP15184741.5T patent/LT3006036T/lt unknown
- 2011-03-22 WO PCT/IB2011/001010 patent/WO2012001469A1/en not_active Ceased
- 2011-03-22 CN CN201610887523.1A patent/CN106924716A/zh active Pending
- 2011-03-22 HU HUE11728387A patent/HUE027417T2/en unknown
- 2011-03-22 PL PL11728387T patent/PL2550007T3/pl unknown
- 2011-03-22 DK DK11728387.9T patent/DK2550007T3/en active
- 2011-03-22 RS RS20190058A patent/RS58224B1/sr unknown
-
2013
- 2013-12-30 US US14/143,866 patent/US10137167B2/en active Active
-
2016
- 2016-04-07 JP JP2016077478A patent/JP6297616B2/ja active Active
-
2017
- 2017-12-14 JP JP2017239240A patent/JP6545778B2/ja active Active
-
2018
- 2018-10-17 US US16/162,453 patent/US11020448B2/en active Active
-
2019
- 2019-01-16 HR HRP20190104TT patent/HRP20190104T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2462465T3 (es) | Desmopresina bucodispersable para aumentar el periodo inicial del sueño no alterado por nocturia | |
| ES2559446T3 (es) | Desmopresina para reducir micciones nocturnas | |
| US11963995B2 (en) | Methods comprising desmopressin | |
| HK40002265A (en) | Desmopressin for reducing nocturnal voids | |
| HK1238572B (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1238572A1 (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1236847B (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1236847A1 (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1179156B (en) | Desmopressin for reducing nocturnal voids | |
| HK1196253B (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1228266A1 (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1196253A (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia |